Risankizumab Effective in Moderate-to-Severe Plaque Psoriasis Risankizumab Effective in Moderate-to-Severe Plaque Psoriasis

Risankizumab, a monoclonal antibody that binds to the p19 subunit of interleukin-23, is effective for treating moderate-to-severe plaque psoriasis, according to results from two phase 3 trials.Reuters Health Information

Source: Medscape Medical News Headlines - August 20, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news